Naltrexone for the treatment of obesity: Review and update

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1841-1845

  Lee, Michael William ^a   Fujioka, Ken ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Bupropion; Naltrexone; Pharmacotherapy; Weight loss

Indexed keywords

AMFEBUTAMONE; NALTREXONE; OPIATE PEPTIDE; PLACEBO; PROOPIOMELANOCORTIN;

DRUG EFFECT; DRUG INHIBITION; DRUG SAFETY; FEEDING BEHAVIOR; FOOD INTAKE; HUMAN; NERVE CELL; NONHUMAN; OBESITY; REVIEW;

ANIMALS; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY, COMBINATION; FEEDING BEHAVIOR; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; OPIOID PEPTIDES; WEIGHT LOSS;

EID: 68149166586     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903048959     Document Type: Review

References (30)

1. Holtzman SG. Suppression of appetitive behaviour in the rat by naloxone: lack of prior morphine dependence. Life Sci 1979;24:219-226
2. Bodnar RJ. Opioid receptor subtype antagonists and ingestion. In: Cooper SJ, Clifton PG, editors, Drug receptor subtypes and ingestive behaviour. London: Academic Press; 1996. p. 127-146
3. Gosnell B, Levine AS. Stimulation of ingestive behaviour by preferential and selective opioid agonists. In: Cooper SJ, Clifton PG, editors, Drug receptor subtypes and ingestive behaviour. San Diego: Academic Press; 1996. p. 147-166
4. Tepperman TS, Hirst M, Gowdey CW. Hypothalamic injection of morphine: feeding and temperature responses. Life Sci 1981;28:2459-2467 (Pubitemid 11094753)
5. Evans KR, Vaccarino AL. Amphetamine-induced and morphine-induced feeding - evidence for involvement in reward processes. Neurosci Biobehav Rev 1990;14:9-22
6. Dum J, Gramsch C, Herz A. Activation of hypothalamic beta-endorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav 1983;18:443-447 (Pubitemid 13146904)
7. Yamamoto T, Sako N, Maeda S. Effects of taste stimulation on beta-endorphin levels in rat cerebrospinal fluid and plasma. Physiol Behav 2000;69:345-350 (Pubitemid 30408594)
8. Cooper SJ, Kirkham TC. Basic mechanisms of opioids' effects on eating and drinking. In: Reid LD, editor. Opioids, bulimia and alcohol abuse and alcoholism. New York: Springer; 1990. p. 91-110
9. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002;26:713-728
10. Morley JE, Parker S, Levine AS. Effect of butorphanol tartrate on food and water consumption in humans. Am J Clin Nutr 1985;42:1175-1178 (Pubitemid 16166013)
11. Drewnowski A, Krahn DD, Demitrack MA, et al. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 1992;51:371-379
12. Facchinetti F, Giovannini C, Barletta C, et al. Hyperendorphinemia in obesity and relationships to affective state. Physiol Behav 1986;36:937-940 (Pubitemid 16105063)
13. Scavo D, Barletta C, Vagini D, et al. Hyperendorphinemia in obesity is not related to the affective state. Physiol Behav 1990;48:681-683
14. Shader RI. Antagonists, inverse agonists, and protagonists. J Clin Psychopharmacol 2003;23:321-322
15. Vivitrol prescribing information, October 2007. Alkermes, Inc./Cephalon, Inc
16. Sternbach HA, Annitto W, Pottash ALC, et al. Anorexic effects of naltrexone in man. Lancet 1982;1:388-389
17. Bertino M, Beauchamp GK, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. Am J Physiol 1991;261:R59-63
18. Yeomans MR, Gray RW. Selective effects of naltrexone on food pleasantness and intake. Physiol Behav 1996;60:439-446 (Pubitemid 26274284)
19. Yeomans MR, Gray RW. Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetiser effect. Physiol Behav 1997;62:15-21
20. Spiegel TA, Stunkard AJ, Shrager EE, et al. Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav 1987;40:135-141 (Pubitemid 17096811)
21. Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985;38:419-422 (Pubitemid 16250316)
22. Maggio CA, Presta E, Bracco EF, et al. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Res Bull 1985;14:657-661 (Pubitemid 16239703)
23. Malcolm R, O'Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes 1985;9:347-353 (Pubitemid 16201361)
24. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003;349:926-928 (Pubitemid 37064764)
25. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005;8:571-578 (Pubitemid 40594196)
26. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-641 (Pubitemid 135688262)
27. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2008;17:30-39
28. Fujioka K, Lee MW. Pharmacologic treatment options for obesity: current and potential medications. Nutr Clin Pract 2007;22:50-54 (Pubitemid 46175472)
29. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: developing products for weight management. February 2007. Available from: http://www.fda.gov/cder/guidance/7544dft.htm.
30. Available from: http://www.orexigen.com/trials. [Accessed 17 May 2009]